Postoperative Pain, AcuteShoulder PainSerratus Posterior Superior Intercostal Plane Block
Investigational drug(s) / intervention(s)
Group SPSIP: Serratus Posterior Superior İntercostal Plane Block (SPSIP)
Group SPSIP: Serratus Posterior Superior İntercostal Plane Block (SPSIP): Serratus Posterior Superior İntercostal Plane (SPSIP) Block will be performed before the surgery in seated position, under standard sterilization conditions.A linear ultrasound probe will be placed in the sagittal plane along the medial border of the scapula, and the second and third ribs, relevant muscles, and the pleura will be identified.
The needle will be advanced into the interfascial plane between the serratus posterior superior and intercostal muscles. After confirmation with salin injection , the block will be performed by injecting 30 mL of 0.25% bupivacaine, and the cranio-caudal spread will be visualized under ultrasound.
Study summary
This study aimed to evaluate the effectiveness of serratus posterior superior intercostal plane (SPSIP) block in managing postoperative pain in patients undergoing arthroscopic shoulder surgery.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* Classified as American Society of Anesthesiologists (ASA) physical status I-II-III
* Scheduled for elective shoulder arthroscopy surgery
* Surgery performed under general anesthesia
* Provision of written informed consent
Exclusion Criteria:
* Use of anticoagulant or antiplatelet medications
* Presence of bleeding diathesis or coagulation disorders
* Known allergy or hypersensitivity to local anesthetics or opioid medications
* Infection or history of previous surgery at the planned block site
* Alcohol or drug dependence
* Cognitive impairment preventing reliable pain assessment using the NRS
* Pregnancy or lactation
* Diabetes mellitus
* Renal or hepatic impairment
Primary outcome measure(s)
Postoperative 48-Hour PCA Opioid Consumption — Postoperative 0-8, 8-16, 16-24, 24-48 intervals Total amount of opioid delivered by the patient-controlled analgesia (PCA) device during the first 48 hours after surgery, recorded in milligrams(mg)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.